The Clematis study was the first industry-sponsored, Phase 2, double-blind, placebo-controlled clinical trial in Down syndrome. The study was designed to evaluate the safety and potential benefit of basmisanil treatment on the intellectual disability associated with Down syndrome. Earlier this year, the study results were published and discussed in a scientific journal. The purpose of this webinar will be to meet with the authors who will explain the Clematis study results and share insights from the Seahorse study in children with Down syndrome.
04/26922
Source: LuMind IDSC